Robert W. Baird Lowers ICON Public (NASDAQ:ICLR) Price Target to $203.00

ICON Public (NASDAQ:ICLR) had its price target decreased by equities research analysts at Robert W. Baird from $221.00 to $203.00 in a report issued on Tuesday,Benzinga reports. The firm presently has a “neutral” rating on the medical research company’s stock. Robert W. Baird’s target price would suggest a potential upside of 8.85% from the stock’s current price.

A number of other equities analysts have also recently issued reports on ICLR. Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 target price on shares of ICON Public in a report on Wednesday, January 15th. Barclays dropped their target price on ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a report on Friday, February 21st. William Blair reissued an “outperform” rating on shares of ICON Public in a report on Tuesday, January 14th. Truist Financial dropped their target price on ICON Public from $284.00 to $262.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $255.00 price target (down from $270.00) on shares of ICON Public in a report on Tuesday, November 19th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $279.17.

ICON Public Price Performance

Shares of ICLR stock opened at $186.49 on Tuesday. The stock has a 50 day moving average of $200.78 and a two-hundred day moving average of $238.28. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36. ICON Public has a 12 month low of $179.50 and a 12 month high of $347.72. The company has a market capitalization of $15.06 billion, a P/E ratio of 19.57, a P/E/G ratio of 1.86 and a beta of 1.21.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. As a group, equities analysts expect that ICON Public will post 13.38 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Natixis Advisors LLC boosted its position in shares of ICON Public by 6.7% in the 4th quarter. Natixis Advisors LLC now owns 177,761 shares of the medical research company’s stock worth $37,279,000 after purchasing an additional 11,177 shares during the last quarter. State of Tennessee Department of Treasury boosted its position in shares of ICON Public by 1.0% in the 4th quarter. State of Tennessee Department of Treasury now owns 158,947 shares of the medical research company’s stock worth $33,333,000 after purchasing an additional 1,600 shares during the last quarter. Kornitzer Capital Management Inc. KS boosted its position in shares of ICON Public by 40.6% in the 4th quarter. Kornitzer Capital Management Inc. KS now owns 97,102 shares of the medical research company’s stock worth $20,363,000 after purchasing an additional 28,050 shares during the last quarter. Motley Fool Wealth Management LLC boosted its position in shares of ICON Public by 2.3% in the 4th quarter. Motley Fool Wealth Management LLC now owns 64,038 shares of the medical research company’s stock worth $13,342,000 after purchasing an additional 1,466 shares during the last quarter. Finally, Foyston Gordon & Payne Inc boosted its position in shares of ICON Public by 27.3% in the 4th quarter. Foyston Gordon & Payne Inc now owns 51,713 shares of the medical research company’s stock worth $10,845,000 after purchasing an additional 11,089 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.